A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
NCT ID: NCT06741397
Last Updated: 2025-11-18
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
PHASE2
Total Enrollment
229 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-12-20
Study Completion Date
2029-01-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a new formulation of Cabotegravir (CAB) dosed every 4-months (Q4M) for pre-exposure prophylaxis (PrEP) in participants at risk of HIV-1 acquisition.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers
NCT02478463
Infection, Human Immunodeficiency Virus
HIV Infections
COMPLETED
PHASE1
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults
NCT06786520
HIV Infections
ACTIVE_NOT_RECRUITING
PHASE1
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants
NCT06033547
HIV Infections
COMPLETED
PHASE1
Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants
NCT04484337
HIV Infections
COMPLETED
PHASE1
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males
NCT04692077
HIV Infections
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
HIV Infections
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
SINGLE_GROUP
Primary Study Purpose
OTHER
Blinding Strategy
NONE
This is an open label study.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CAB Group
Participants receive lead-in injections comprising cabotegravir LA during month one and injections of a new formulation of CAB LA at Month 3, Month 5 and every 4 months thereafter to Month 29.
Group Type
EXPERIMENTAL
CAB LA
Intervention Type
DRUG
Injections administered IM gluteal.
New formulation of CAB LA
Intervention Type
DRUG
Injections administered IM gluteal.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CAB LA
Injections administered IM gluteal.
Intervention Type
DRUG
New formulation of CAB LA
Injections administered IM gluteal.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. At the time of obtaining informed consent, adolescent and adult participants weighing at least 35 kg.
2. Participants must have a nonreactive HIV test at Screening (rapid test, nonrapid HIV immunoassay, and HIV RNA) and enrollment (a rapid test, nonrapid HIV immunoassay, and HIV RNA).
3. Participants who are at risk of acquiring HIV, defined as having had anal or vaginal sex in the past 6 months.
4. Participants who are overtly healthy as determined by medical evaluation by a responsible and experienced physician, including medical history, physical examination, laboratory tests and cardiac monitoring at the time of screening.
5. No alcohol or substance use that, in the opinion of the study investigator and medical monitor, would interfere with the conduct of the study (e.g., provided by self-report, or found upon medical history and examination or in available medical records).
6. Participants who have received oral PrEP are eligible, but they must discontinue oral PrEP within 10 days of Day 1 visit.
7. Male or female at birth, (transgender individuals are not excluded). Contraceptive use should align with local regulations. Participants assigned female at birth must not be pregnant or breastfeeding and must either not be of childbearing potential (POCBP) or use highly effective contraception. A POCBP must have a negative pregnancy test within 30 days before dosing.
8. Participants must be \>=16 years old, of legal age to consent to sexual intercourse, and capable of giving written informed consent. Adolescents must provide written informed assent/consent and/or obtain parental/guardian consent if not of legal age, as per site SOPs and IRB/EC policies.
2. Participants must have a nonreactive HIV test at Screening (rapid test, nonrapid HIV immunoassay, and HIV RNA) and enrollment (a rapid test, nonrapid HIV immunoassay, and HIV RNA).
3. Participants who are at risk of acquiring HIV, defined as having had anal or vaginal sex in the past 6 months.
4. Participants who are overtly healthy as determined by medical evaluation by a responsible and experienced physician, including medical history, physical examination, laboratory tests and cardiac monitoring at the time of screening.
5. No alcohol or substance use that, in the opinion of the study investigator and medical monitor, would interfere with the conduct of the study (e.g., provided by self-report, or found upon medical history and examination or in available medical records).
6. Participants who have received oral PrEP are eligible, but they must discontinue oral PrEP within 10 days of Day 1 visit.
7. Male or female at birth, (transgender individuals are not excluded). Contraceptive use should align with local regulations. Participants assigned female at birth must not be pregnant or breastfeeding and must either not be of childbearing potential (POCBP) or use highly effective contraception. A POCBP must have a negative pregnancy test within 30 days before dosing.
8. Participants must be \>=16 years old, of legal age to consent to sexual intercourse, and capable of giving written informed consent. Adolescents must provide written informed assent/consent and/or obtain parental/guardian consent if not of legal age, as per site SOPs and IRB/EC policies.
Exclusion Criteria
1. One or more reactive or positive HIV test results at Screening or Enrollment, even if HIV infection was not confirmed.
2. Participants who are breastfeeding or plan to become pregnant or breastfeed during the study.
3. Alanine aminotransferase (ALT) \>=3 times the upper limit of normal (ULN).
4. Evidence of active Hepatitis B virus (HBV) infection.
* Participants positive for HBsAg or HBV DNA are excluded.
* Participants negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and positive for HBV DNA are excluded.
5. Unstable liver disease, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
6. History of clinically relevant hepatitis within last 6 months.
7. Known history of liver cirrhosis with or without viral hepatitis co-infection.
8. Participants with Hepatitis C virus (HCV) co-infection will be allowed entry into this study if:
* Liver enzymes meet entry criteria.
* HCV Disease has undergone appropriate work-up, and is not advanced, and will not require treatment prior to the primary endpoint (e.g., Month 13).
* In the event that recent biopsy or imaging data is not available or inconclusive, the Fibrosis 4 (Fib-4) score will be used to verify eligibility:
i. Fib-4 score greater than (\>) 3.25 is exclusionary. ii. Fib-4 scores 1.45 - 3.25 requires Medical Monitor consultation. Fibrosis 4 score Formula: (Age x AST) / (Platelets x (sqr \[ ALT\]) It is approved by the Medical Monitor.
9. Estimated glomerular filtration rate of \<30 mL/min/1.73 m\^2 via CKD-EPIcr\_R (2021) method.
10. Any acute laboratory abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's participation in the study of an investigational compound.
11. Any verified Grade 4 laboratory abnormality, with the exception of Grade 4 \[triglycerides or lipid abnormalities\].
12. Participants determined by the Investigator to have a high risk of seizures, A participant with a prior history of seizure may be considered for enrolment if the Investigator believes the risk of seizure recurrence is low. All cases of prior seizure history should be discussed with the Medical Monitor prior to enrolment.
13. Participant is currently participating in or has participated in a study with a compound or device that is not commercially available within 30 days of signing informed consent, unless permission from the Medical Monitor is granted.
14. Presence of any history of allergy/sensitivity to any of the study drug.
15. Inflammatory skin conditions that compromise the safety of IM injections, per the discretion of the investigator.
16. Participant has an implant/enhancement (including fillers) at the area of proposed injection (e.g., gluteus medius); or tattoo or other dermatological condition overlying the area for IM (e.g., gluteus medius) or any other area which may significantly interfere with interpretation of injection site reactions.
17. Current or anticipated need for chronic anti-coagulants or active coagulopathy (primary or iatrogenic) which would contraindicate IM injection.
18. Ongoing or clinically relevant pancreatitis.
19. Clinically significant cardiovascular disease or history of clinically significant cardiovascular disease.
20. All participants will be screened for STIs (e.g., chlamydia, gonorrhea, trichomoniasis, syphilis). Participants with untreated infections are excluded. Participants may be rescreened at least 24 hours after completion of STI treatment.
21. History or presence of sensitivity to any of the study medications or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation. In addition, if heparin is used during PK sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled.
22. Ongoing uncontrolled malignancy is excluded, whereas participants who have controlled localized malignancies may be included on agreement between the investigator and the Medical Monitor.
23. Participants who in the investigator's judgment, poses a significant suicidality risk.
24. Any pre-existing physical or mental condition (including substance abuse disorder) which, in the opinion of the Investigator or the medical monitor, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
25. Any condition which, in the opinion of the Investigator or the medical monitor, may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive IM medication.
26. Co-enrollment in any other interventional research study or other concurrent studies which may have interfered with this study (as provided by self-report or other available documentation). Exceptions for non-interventional studies may be made if appropriate after consultation with the Medical Monitor.
27. Participants receiving any protocol-prohibited medication and who are unwilling or unable to switch to an alternate medication.
28. Use of antiretroviral therapy (ART) for Postexposure Prophylaxis within the 90 days prior to Day 1.
29. Use of CAB LA for PrEP at any time prior to Screening.
30. Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of IP.
31. Anticipated need for HCV therapy with interferon or any drugs that have potential for adverse drug:drug interactions with study treatment throughout the entire study period.
32. Treatment with an HIV-1 preventive vaccine within 90 days of Screening.
33. Participant is unlikely to adhere to the study procedures, keep appointments, is planning to relocate during the study, or remain on study through to its conclusion.
34. Participants who are considered high-risk, meeting at least one of the following criteria:
* Participant who has exchanged condomless sex for goods or money within the past 12 months prior to Screening.
* Participant who has used recreational intravenous drugs within the past 12 months prior to Screening.
* Participant who has participated in Chemsex practice (such as the use of cocaine, crack cocaine, methamphetamine, ketamine, 3,4-methlenedioxy-methamphetamine, GHB, mephedrone or prescription drugs apart from those prescribed by a licensed provider) within the past 6 months prior to Screening.
* Participant with any STI in the last 6 months also reporting any partners for condomless sex.
* Participant who has condomless sex with a serodiscordant partner who has a detectable viral load or is not on ART.
* Participant with any other behavior assessed by the investigator as high-risk sexual behavior.
35. Participant has in the last 14 days prior to Screening presented with signs and symptoms, which, in the opinion of the investigator, are suggestive of acute HIV infection. Participants may only be enrolled if clinical suspicion of HIV is ruled out with non-reactive results.
36. Participant becomes a ward of state (e.g., child in care).
2. Participants who are breastfeeding or plan to become pregnant or breastfeed during the study.
3. Alanine aminotransferase (ALT) \>=3 times the upper limit of normal (ULN).
4. Evidence of active Hepatitis B virus (HBV) infection.
* Participants positive for HBsAg or HBV DNA are excluded.
* Participants negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and positive for HBV DNA are excluded.
5. Unstable liver disease, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
6. History of clinically relevant hepatitis within last 6 months.
7. Known history of liver cirrhosis with or without viral hepatitis co-infection.
8. Participants with Hepatitis C virus (HCV) co-infection will be allowed entry into this study if:
* Liver enzymes meet entry criteria.
* HCV Disease has undergone appropriate work-up, and is not advanced, and will not require treatment prior to the primary endpoint (e.g., Month 13).
* In the event that recent biopsy or imaging data is not available or inconclusive, the Fibrosis 4 (Fib-4) score will be used to verify eligibility:
i. Fib-4 score greater than (\>) 3.25 is exclusionary. ii. Fib-4 scores 1.45 - 3.25 requires Medical Monitor consultation. Fibrosis 4 score Formula: (Age x AST) / (Platelets x (sqr \[ ALT\]) It is approved by the Medical Monitor.
9. Estimated glomerular filtration rate of \<30 mL/min/1.73 m\^2 via CKD-EPIcr\_R (2021) method.
10. Any acute laboratory abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's participation in the study of an investigational compound.
11. Any verified Grade 4 laboratory abnormality, with the exception of Grade 4 \[triglycerides or lipid abnormalities\].
12. Participants determined by the Investigator to have a high risk of seizures, A participant with a prior history of seizure may be considered for enrolment if the Investigator believes the risk of seizure recurrence is low. All cases of prior seizure history should be discussed with the Medical Monitor prior to enrolment.
13. Participant is currently participating in or has participated in a study with a compound or device that is not commercially available within 30 days of signing informed consent, unless permission from the Medical Monitor is granted.
14. Presence of any history of allergy/sensitivity to any of the study drug.
15. Inflammatory skin conditions that compromise the safety of IM injections, per the discretion of the investigator.
16. Participant has an implant/enhancement (including fillers) at the area of proposed injection (e.g., gluteus medius); or tattoo or other dermatological condition overlying the area for IM (e.g., gluteus medius) or any other area which may significantly interfere with interpretation of injection site reactions.
17. Current or anticipated need for chronic anti-coagulants or active coagulopathy (primary or iatrogenic) which would contraindicate IM injection.
18. Ongoing or clinically relevant pancreatitis.
19. Clinically significant cardiovascular disease or history of clinically significant cardiovascular disease.
20. All participants will be screened for STIs (e.g., chlamydia, gonorrhea, trichomoniasis, syphilis). Participants with untreated infections are excluded. Participants may be rescreened at least 24 hours after completion of STI treatment.
21. History or presence of sensitivity to any of the study medications or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation. In addition, if heparin is used during PK sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled.
22. Ongoing uncontrolled malignancy is excluded, whereas participants who have controlled localized malignancies may be included on agreement between the investigator and the Medical Monitor.
23. Participants who in the investigator's judgment, poses a significant suicidality risk.
24. Any pre-existing physical or mental condition (including substance abuse disorder) which, in the opinion of the Investigator or the medical monitor, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
25. Any condition which, in the opinion of the Investigator or the medical monitor, may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to receive IM medication.
26. Co-enrollment in any other interventional research study or other concurrent studies which may have interfered with this study (as provided by self-report or other available documentation). Exceptions for non-interventional studies may be made if appropriate after consultation with the Medical Monitor.
27. Participants receiving any protocol-prohibited medication and who are unwilling or unable to switch to an alternate medication.
28. Use of antiretroviral therapy (ART) for Postexposure Prophylaxis within the 90 days prior to Day 1.
29. Use of CAB LA for PrEP at any time prior to Screening.
30. Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of IP.
31. Anticipated need for HCV therapy with interferon or any drugs that have potential for adverse drug:drug interactions with study treatment throughout the entire study period.
32. Treatment with an HIV-1 preventive vaccine within 90 days of Screening.
33. Participant is unlikely to adhere to the study procedures, keep appointments, is planning to relocate during the study, or remain on study through to its conclusion.
34. Participants who are considered high-risk, meeting at least one of the following criteria:
* Participant who has exchanged condomless sex for goods or money within the past 12 months prior to Screening.
* Participant who has used recreational intravenous drugs within the past 12 months prior to Screening.
* Participant who has participated in Chemsex practice (such as the use of cocaine, crack cocaine, methamphetamine, ketamine, 3,4-methlenedioxy-methamphetamine, GHB, mephedrone or prescription drugs apart from those prescribed by a licensed provider) within the past 6 months prior to Screening.
* Participant with any STI in the last 6 months also reporting any partners for condomless sex.
* Participant who has condomless sex with a serodiscordant partner who has a detectable viral load or is not on ART.
* Participant with any other behavior assessed by the investigator as high-risk sexual behavior.
35. Participant has in the last 14 days prior to Screening presented with signs and symptoms, which, in the opinion of the investigator, are suggestive of acute HIV infection. Participants may only be enrolled if clinical suspicion of HIV is ruled out with non-reactive results.
36. Participant becomes a ward of state (e.g., child in care).
Minimum Eligible Age
16 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ViiV Healthcare
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Birmingham, Alabama, United States
Site Status
GSK Investigational Site
Los Angeles, California, United States
Site Status
GSK Investigational Site
Los Angeles, California, United States
Site Status
GSK Investigational Site
Los Angeles, California, United States
Site Status
GSK Investigational Site
Los Angeles, California, United States
Site Status
GSK Investigational Site
Palm Springs, California, United States
Site Status
GSK Investigational Site
Doral, Florida, United States
Site Status
GSK Investigational Site
Ft. Pierce, Florida, United States
Site Status
GSK Investigational Site
Orlando, Florida, United States
Site Status
GSK Investigational Site
West Palm Beach, Florida, United States
Site Status
GSK Investigational Site
Chicago, Illinois, United States
Site Status
GSK Investigational Site
New Orleans, Louisiana, United States
Site Status
GSK Investigational Site
Springfield, Massachusetts, United States
Site Status
GSK Investigational Site
Berkley, Michigan, United States
Site Status
GSK Investigational Site
Kansas City, Missouri, United States
Site Status
GSK Investigational Site
Las Vegas, Nevada, United States
Site Status
GSK Investigational Site
New York, New York, United States
Site Status
GSK Investigational Site
Valhalla, New York, United States
Site Status
GSK Investigational Site
Greensboro, North Carolina, United States
Site Status
GSK Investigational Site
Cincinnati, Ohio, United States
Site Status
GSK Investigational Site
Columbus, Ohio, United States
Site Status
GSK Investigational Site
Pittsburgh, Pennsylvania, United States
Site Status
GSK Investigational Site
Dallas, Texas, United States
Site Status
GSK Investigational Site
Fort Worth, Texas, United States
Site Status
GSK Investigational Site
Seattle, Washington, United States
Site Status
GSK Investigational Site
San Juan, , Puerto Rico
Site Status
GSK Investigational Site
San Juan, , Puerto Rico
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Puerto Rico
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-000061-24
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
219230
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females
NCT04824131
COMPLETED
PHASE2
Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men
NCT02720094
COMPLETED
PHASE2/PHASE3
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
NCT05418868
RECRUITING
PHASE1
Safety and Anti-HIV Activity of Capravirine Alone and in Combination With Other Anti-HIV Drugs
NCT00005673
COMPLETED
PHASE1
Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254
NCT04507321
COMPLETED
PHASE1
Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures
NCT06405464
RECRUITING
TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278
NCT01031589
COMPLETED
PHASE1
An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.
NCT00081588
COMPLETED
PHASE2
Study in Healthy Volunteers of the Safety and Metabolism of Different Doses of the Anti-HIV Drug TMC278LA.
NCT01275443
COMPLETED
PHASE1
First Time in Human Study of Long Acting VH4524184 Formulations
NCT06310551
RECRUITING
PHASE1
A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials
NCT02187107
COMPLETED
PHASE2
A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants
NCT01656018
COMPLETED
PHASE1
TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment Options
NCT00115050
COMPLETED
PHASE3
A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074
NCT02511990
COMPLETED
PHASE1
Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel
NCT00561496
COMPLETED
PHASE1
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults
NCT06012136
ACTIVE_NOT_RECRUITING
PHASE1
Phase I Trial of S-1153 in Patients With HIV Infection
NCT00002214
COMPLETED
PHASE1
Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents
NCT01721109
COMPLETED
PHASE2/PHASE3
TMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) Previously
NCT00513513
TERMINATED
PHASE2
Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine
NCT03078556
COMPLETED
PHASE1
A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults
NCT04900038
TERMINATED
PHASE2
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05979311
ACTIVE_NOT_RECRUITING
PHASE3
A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1
NCT06061081
TERMINATED
PHASE2
Pharmacokinetics of Lamivudine at Two Different Doses
NCT00985647
COMPLETED
PHASE1/PHASE2